
Biologics
Latest News
Advertisement
Latest Videos

Advertisement
More News

At the moment, Simlandi (adalimumab-ryvk) has the high-concentration, citrate-free, interchangeable Humira (adalimumab) market to itself.

The large pharmacy benefit managers have switched up their coverage of biosimilars, especially the biosimilars to Humira (adalimumab).

Acceptance is greater in oncology than in other specialties.

Challenges with biosimilars and unbranded biologics are discussed and how can they be improved.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Medicare Part D redesign reshapes market
2
The sleep doctor who lives with a disorder he treats
3
Rural health is ailing. Is $50 billion enough to heal it?
4
Managing Chronic Disease Shouldn't Feel Like a Full-Time Job
5























